The phase III TULIP study evaluated SYD985 against physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with progression during or after two HER2-targeted therapies or after T-DM1. Here, ERBB2 is linked to breast cancer.